Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 30.00 | |
5 mg | In stock | $ 43.00 | |
10 mg | In stock | $ 67.00 | |
25 mg | In stock | $ 121.00 | |
50 mg | In stock | $ 202.00 | |
100 mg | In stock | $ 343.00 | |
200 mg | In stock | $ 516.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 48.00 |
Description | Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. |
In vitro | Fatostatin directly binds SCAP and blocks its ER-to-Golgi transport with IC50 of 2.5 and 10 μM in mammalian cells[1]. Fatostatin (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin inhibits insulin-induced adipogenesis of 3T3-L1 cells[2]. |
In vivo | Fatostatin (30 mg/kg; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice[1]. |
Molecular Weight | 294.41 |
Formula | C18H18N2S |
CAS No. | 125256-00-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 70 mg/mL (237.76 mM)
H2O: Insoluble
Ethanol: 70 mg/mL (237.76 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fatostatin 125256-00-0 Metabolism Lipid Fatty Acid Synthase mice 125B11 prostate cancer Fatty Acid Synthase (FASN) gene human insulin-induced ob/ob inhibit expression Golgi Inhibitor adipogenesis SREBP-mediated inhibitor